Financial Results for the Fiscal Year
Ended March 31, 2025 (FY2024)

from the beginning

Financial Results for the Fiscal Year Ended March 31, 2025 (FY2024)

• Forward-Looking Statements and Use of Document

• Changes in the Segment Names

• Highlights

• P&L, FCF

• OP Variance Analysis (Q4): Higher sales driven by continued demand

• OP Variance Analysis (Q4 YTD): Contribution from pricing measures and strong sales

• Breakdown of Adjustments of Adjusted Operating Profit (Q4 YTD)

• Free Cash Flow： 128.3B JPY（YoY +63.5 B JPY）

• Revenue by Region: Steady progress globally, driven by US and Europe

• C&V：Significant growth in global sales and profit, driven by US

• TMCS：Revenues and profits increased due to strong sales including one-time factors and the effects of pricing measures

• TBCT:Both sales and profit increased due to accelerated development of the plasma innovation business

• FY25Guidance

• Profit Variance Analysis (FY25 Guidance)

• Impact of Tariff Policies in US

• Product and Regional Development in line with Key Measures

• Dividend Proposal: Continuous increase per shareholder return policy

Reference

• P&L (QoQ)

• SG&A (QoQ)

• SG&A (YoY)

• Adjusted Operating Profit: Adjustments

• CAPEX, Depreciation and Amortization, R&D Expenses

• Cash Flow (Q4)

• Cash Flow (Q4 YTD)

• Foreign Exchange Sensitivity

@

GS26 Mid-term Review & Taking on the Challenge of Global CDMO

• Forward-Looking Statements and Use of Document

• Progress against GS26 Financial Targets (3rdYear) and Forecast

• Trends and Factors Affecting Changes in Operating Profit Margin

• GS26 3rd Year Review (Company-wide)

• GS26 3rd Year Review (C&V)

• GS26 3rd Year Review (TMCS)

• GS26 3rd Year Review (TBCT)

• GS26 3rdYear Review (TBCT) *Excluding exchange rate effects

• "From Devices to Solutions" (Mid-to Long-Term Vision)

• Terumo CDMO’s Unique Business Model

• Terumo CDMO’s Strengths

• Terumo CDMO’s Development Capability = Built-up Technologies

• Terumo CDMO's Solutions

• On-body Injector that Embodies the Deviceuticals Concept

• CDMO Marketand Terumo's Sales Growth

• Terumo CDMO’s Strategy

• Becoming a Leading CDMO Company

@